The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Cytomegalovirus RetinitisHIV Infections
Interventions
DRUG

Fomivirsen sodium

Trial Locations (25)

10028

Vitreo - Retinal Consultants, New York

19102

Hahnemann Univ Hosp, Philadelphia

20036

Dr Alan Palestine, Washington D.C.

23507

Virginia Eye Consultants, Norfolk

27710

Duke Univ, Durham

28204

Charlotte Eye Ear Nose & Throat Association, Charlotte

30322

Emory Univ School of Medicine / Emory Eye Ctr, Atlanta

30327

Georgia Retina, Atlanta

33060

Dr Julio Perez, Fort Lauderdale

33136

Bascon Palmer Eye Institute, Miami

46202

Indiana Univ Med Ctr, Indianapolis

60612

Univ of Illinois, Chicago

70112

Tulane Univ, New Orleans

77004

Vitreoretinal Consultants, Houston

77030

Baylor College of Medicine, Houston

80262

Univ of Colorado Health Sciences Ctr, Denver

90017

Retina - Vitreous Associates Med Group, Los Angeles

92134

San Diego Naval Hosp, San Diego

92715

UCI College of Medicine, Irvine

94110

Univ of California San Francisco / SF Gen Hosp, San Francisco

95128

Santa Clara Valley Med Ctr, San Jose

98104

Novum Inc, Seattle

191461192

Graduate Hosp, Philadelphia

752359057

Univ of Texas Southwestern Med Ctr of Dallas, Dallas

911052536

Community Eye Med Group, Pasadena

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY

NCT00002356 - The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes | Biotech Hunter | Biotech Hunter